Scale-up of lentiviral vectors for gene therapy: advances and challenges

Files

hdl_126186.pdf (201.97 KB)
  (Published version)

Date

2017

Authors

McCarron, A.
Donnelley, M.
Parsons, D.

Editors

Advisors

Journal Title

Journal ISSN

Volume Title

Type:

Journal article

Citation

Cell and Gene Therapy Insights, 2017; 3(9):719-729

Statement of Responsibility

Alexandra McCarron, Martin Donnelley & David Parsons

Conference Name

Abstract

Growing interest in the use of lentiviral (LV) vectors for gene therapy applications has resulted in demand for production processes that are amenable to large scale. However, up-scaling LV manufacturing poses a number of challenges for process developers and regulatory bodies, which need to be overcome in order to cost effectively generate a gene therapy product in large quantities. Recently there has been progress in developing workflows capable of producing and processing LV vector at sufficient levels for human gene therapy applications. Accordingly, this article will cover the current state of LV upstream and downstream processing, ongoing challenges of up-scaling manufacturing, recent advances and improvements, and future perspectives.

School/Discipline

Dissertation Note

Provenance

Description

Published: Nov 16 2017

Access Status

Rights

This work is licensed under a Creative Commons Attribution – NonCommercial – NoDerivatives 4.0 International License

License

Grant ID

Call number

Persistent link to this record